Dr Reddy's Plunges 9% as Semaglutide API Costs and US Generic Erosion Crush Margins

• Quick Take: Dr Reddy's Laboratories shares plunged 9% Thursday as weak Q1 FY27 results revealed margin pressure from semaglutide API ramp costs and softer US generic pricing.
• JM Financial flagged the semaglutide API cost escalation as the primary margin drag, with the active pharmaceutical ingredient business requiring heavy investment before it generates returns.
• Multiple brokerages turned bearish post-results, warning of further downside if US generic base erosion continues into Q2.

Dr Reddy's Laboratories (NSE: DRREDDY) shares fell approximately 9% in Thursday's session after the company reported Q1 FY27 results that disappointed on revenue growth and margins. The earnings miss was concentrated in two areas: elevated API manufacturing costs associated with the semaglutide peptide manufacturing ramp—where Dr Reddy's has invested heavily anticipating the global GLP-1 demand wave—and pressure in the North American generics business where pricing erosion in base portfolio products continued. JM Financial's post-results commentary specifically cited semaglutide API ramp costs as the primary culprit for the margin undershoot.

The semaglutide investment is strategically important but creates near-term pain. Dr Reddy's is among a small group of Indian pharma companies positioning itself to supply API for biosimilar and generic GLP-1 drugs that will come to market as Novo Nordisk's and Eli Lilly's patents begin expiring. The capital-intensive nature of peptide manufacturing means that upfront costs hit the P&L before revenue contributions materialize—a classic "building the factory before selling the product" dynamic. Management has not provided a timeline for when semaglutide revenues will offset the investment costs.

The 9% single-day decline raises technical concerns. Dr Reddy's is among India's most widely held large-cap pharma stocks, and a 9% drawdown typically triggers stop-losses from foreign institutional investors holding the stock on momentum rather than fundamental conviction. The question for investors is whether the semaglutide bet—if it pays off in FY28-29—justifies holding through a period of margin depression. Bearish brokerages see continued risk into Q2 if US generic price erosion does not stabilize.